中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Science
Anti-viral Platform
RNA Interference
Fatty Liver Disease
Products & Pipeline
Overview
HCV
HBV
HIV
Partnership
Investors
Financials & Filing
Presentation Materials
News
2020
2019
2018
2017
2016
2015
2014
Careers
2020
2019
2018
2017
2016
2015
2014
First HBV Patient Dosed in Phase IIa Clinical Trial of ASC22, a Subcutaneously Administered PD-L1 Antibody
2020-08-17
Ascletis’ All-oral HCV Treatment Approved for Marketing in China
2020-07-31
Bridging Study in China Completed for NASH Drug Candidate ASC40
2020-07-20
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
2020-06-17
Ascletis’THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
2020-05-13
«
1
2
3
4
»
